Hemodynamic monitoring, the measurement of a patient’s blood circulation and cardiac function, enables clinicians to evaluate whether a patient is receiving enough oxygen to their organs and tissues.
The device includes visual clinical support screens and is compatible with the Edwards Swan-Ganz pulmonary artery catheter and Oximetry catheters.
“The HemoSphere advanced monitor enables simplified visual clinical support, which is particularly important in the care of our most complex critically ill patients,” Dr. Marco Maggiorini, head of the medical ICU at University Hospital Zurich, said in prepared remarks. “Clinicians can choose the clinical support screens that best suit their needs, enabling proactive decisions on behalf of their patients.”
Irvine, Calif.-based Edwards’s HemoSphere blood flow monitoring platform is not yet approved for commercial use in the U.S.
“The HemoSphere advanced monitor provides a strong foundation for Edwards to continue to innovate and advance new hemodynamic solutions, now and in the future,” Edwards’ corporate VP of critical care Catherine Szyman added. “The design of this monitoring platform enables clinicians to treat their patients using more customized, informative and advanced parameters.”
The company’s shares rose last month in response to the company posting a positive outlook for 2017, despite 4th quarter numbers sliding towards the lower end of its guidance.
The company said that for the next year, it expects to bring in global sales between $3 billion and $3.4 billion, with adjusted earnings per share of between $3.30 and $3.45.